As backlash mounts in the wake of a disastrous PhIII flop, Eisai goes deeper with 2 new hires
While Biogen buckles under intense criticism for the Phase III failure of aducanumab for Alzheimer’s — triggering a review of what it should focus on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
